RADICAVA® Oral Suspension Now Available in Canada

FRIDAY, FEBRUARY 10TH, 2023

Mitsubishi Tanabe Pharma Canada announces that RADICAVA® Oral Suspension (oral edaravone) is now commercially available in Canada to treat patients with amyotrophic lateral sclerosis (ALS). 

RADICAVA® Oral Suspension was developed to have similar efficacy to RADICAVA® IV Infusion, which was authorized by Health Canada for the treatment of ALS in October 2018 and has shown in a pivotal trial to slow the loss of physical function in ALS.

Following the positive recommendations from INESSS and CADTH, Mitsubishi Tanabe Pharma Canada continues working with the necessary stakeholders to ensure timely access to RADICAVA® Oral Suspension for Canadians living with ALS through private insurance and public formularies.